Zogenix announces positive results for ZX008 in Dravet syndrome

Statistically significant convulsive seizure reduction seen, and all key secondary endpoints met
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
EMERYVILLE, Calif.—Zogenix Inc., a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, in July reported positive top-line results from its second confirmatory Phase 3 study (Study 1504) for its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of children and young adults with Dravet syndrome.
 
According to Zogenix, the study successfully met the primary endpoint and all key secondary endpoints, demonstrating that ZX008, at a dose of 0.5 mg/kg/day (maximum 20 mg/day), is superior to placebo when added to a stiripentol regimen. The results are consistent with those reported in Study 1, Zogenix’s first pivotal Phase 3 study, the company adds.
 
Keys finding include:
  • Patients taking ZX008 achieved a 54.7-percent greater reduction in mean monthly convulsive seizures compared to placebo. The median reduction in monthly convulsive seizure frequency was 62.7 percent in the ZX008 group, compared to 1.2 percent in placebo patients.
  • ZX008 also demonstrated statistically significant improvement vs. placebo in both key secondary measures, including patients with clinically meaningful reductions (more than 50 percent) in seizure frequency and longest seizure-free interval.
  • ZX008 was generally well tolerated in this study, with the adverse events consistent with those observed in Study 1 and the known safety profile of fenfluramine. No patient exhibited cardiac valvulopathy or pulmonary hypertension at any time in the study.
“These impressive study results show the significant impact the addition of ZX008 made in reducing the burden of convulsive seizures for patients who are not adequately controlled using stiripentol, the standard of care for the treatment of Dravet syndrome in Europe,” said Dr. Rima Nabbout of the Department of Pediatric Neurology, Reference Center for Rare Epilepsies at Necker Enfants Malades Hospital, who was the principal investigator of Study 1504. “If approved, ZX008 has the potential to be a transformative treatment for Dravet syndrome, a rare and serious form of epilepsy with few available treatment options.”

Related Topics

Published In

Volume 14 - Issue 9 | September 2018

September 2018

September 2018 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue